#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	1234	16S	1529	1529	100.0	16S.l15.c17.ctg.1	2158	111.9	1	SNP	n	C1184T	0	.	.	1184	1184	C	1351	1351	C	105	C	64	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	2210	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3785	114.8	0	.	n	.	0	T695C	SNP	695	695	T	1168	1168	C	123	C	68	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	2210	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3785	114.8	0	.	n	.	0	G1337A	SNP	1337	1337	G	1810	1810	A	168	A	111	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	2210	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3785	114.8	0	.	n	.	0	T1971C	SNP	1971	1971	T	2444	2444	C	78	C	48	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	2210	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3785	114.8	1	SNP	n	A2045G	0	.	.	2045	2045	A	2518	2518	A	77	A	53	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	2210	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3785	114.8	1	SNP	n	C2597T	0	.	.	2597	2597	C	3070	3070	C	142	C	89	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	76	folP	852	852	100.0	folP.l6.c4.ctg.1	1155	13.6	1	SNP	p	R228S	1	.	.	682	684	AGC	815	817	AGC	12;12;12	A;G;C	7;8;8	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	513	242	gyrA	2751	2164	99.77	gyrA.l6.c4.ctg.1	2270	15.3	0	.	p	.	0	Y720D	NONSYN	2158	2160	TAC	2261	2263	GAC	5;5;5	G,T;A;C	0,2;3;3	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	513	242	gyrA	2751	2164	99.77	gyrA.l6.c4.ctg.1	2270	15.3	1	SNP	p	S91F	0	.	.	271	273	TCC	374	376	TCC	16;16;16	T;C;C	10;8;9	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	513	242	gyrA	2751	2164	99.77	gyrA.l6.c4.ctg.1	2270	15.3	1	SNP	p	D95G	0	.	.	283	285	GAC	386	388	GAC	19;19;19	G;A;C	10;10;10	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	513	242	gyrA	2751	2164	99.77	gyrA.l6.c4.ctg.1	2270	15.3	1	SNP	p	D95N	0	.	.	283	285	GAC	386	388	GAC	19;19;19	G;A;C	10;10;10	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	513	242	gyrA	2751	437	100.0	gyrA.l6.c4.ctg.2	633	18.1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	539	70	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	912	14.9	0	.	p	.	0	A39T	NONSYN	115	117	GCC	258	260	ACC	18;20;20	A;C;C	11;11;11	.	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	539	70	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	912	14.9	0	.	p	.	0	R44H	NONSYN	130	132	CGC	273	275	CAC	22;22;21	C;A;C	12;10;12	.	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	539	70	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	912	14.9	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	456	458	CAC	15;15;15	C;A;C	11;10;12	.	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	539	70	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	912	14.9	1	SNP	p	G45D	0	.	.	133	135	GGC	276	278	GGC	21;21;21	G;G;C	12;12;12	mtrR.WHO_G_01393:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	86	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	696	22.0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	519	208	parC	2304	2153	99.95	parC.l6.c4.ctg.1	2283	16.6	0	.	p	.	0	G708S	NONSYN	2122	2124	GGC	2252	2254	AGC	3;3;3	A,G;G;C	1,1;2;1	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	519	208	parC	2304	2153	99.95	parC.l6.c4.ctg.1	2283	16.6	1	SNP	p	D86N	0	.	.	256	258	GAC	386	388	GAC	14;14;14	G;A;C	7;8;9	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	519	208	parC	2304	2153	99.95	parC.l6.c4.ctg.1	2283	16.6	1	SNP	p	S87W	0	.	.	259	261	AGT	389	391	AGT	14;14;14	A;G;T	8;9;9	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	519	208	parC	2304	2153	99.95	parC.l6.c4.ctg.1	2283	16.6	1	SNP	p	S87R	0	.	.	259	261	AGT	389	391	AGT	14;14;14	A;G;T	8;9;9	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	519	208	parC	2304	2153	99.95	parC.l6.c4.ctg.1	2283	16.6	1	SNP	p	S87I	0	.	.	259	261	AGT	389	391	AGT	14;14;14	A;G;T	8;9;9	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	519	208	parC	2304	2153	99.95	parC.l6.c4.ctg.1	2283	16.6	1	SNP	p	S88P	0	.	.	262	264	TCC	392	394	TCC	14;14;14	T;C;C	8;9;9	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	519	208	parC	2304	298	97.65	parC.l6.c4.ctg.2	543	4.7	0	.	p	.	0	D671A	NONSYN	2011	2013	GAC	53	55	GCC	1;1;1	G;C;C	0;0;0	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	519	208	parC	2304	298	97.65	parC.l6.c4.ctg.2	543	4.7	0	.	p	.	0	C672trunc	TRUNC	2014	2014	T	56	56	T	1	T	0	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	519	208	parC	2304	298	97.65	parC.l6.c4.ctg.2	543	4.7	0	.	p	.	0	I674T	NONSYN	2020	2022	ATC	62	64	ACC	1;1;1	A;C;C	0;0;0	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	519	208	parC	2304	298	97.65	parC.l6.c4.ctg.2	543	4.7	0	.	p	.	0	I675M	NONSYN	2023	2025	ATT	65	67	ATG	1;1;1	A;T;G	0;0;0	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	519	208	parC	2304	298	97.65	parC.l6.c4.ctg.2	543	4.7	0	.	p	.	0	F686S	NONSYN	2056	2058	TTC	98	100	TCC	1;1;1	T;C;C	0;0;0	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	519	208	parC	2304	298	97.65	parC.l6.c4.ctg.2	543	4.7	0	.	p	.	0	I688T	NONSYN	2062	2064	ATC	104	106	ACC	1;1;1	A;C;C	0;0;0	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	519	208	parC	2304	298	97.65	parC.l6.c4.ctg.2	543	4.7	0	.	p	.	0	M711R	NONSYN	2131	2133	ATG	173	175	AGG	5;5;5	A;G,T;G	3;0,3;3	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	168	parE	1986	1986	100.0	parE.l6.c4.ctg.1	2312	14.5	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1375	1377	GGC	12;12;12	G;G;C	8;8;6	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.56.001	penA.56.001	1	1	531	192	penA	1719	1648	99.7	penA.l15.c4.ctg.1	1742	20.6	0	.	p	.	0	P542H	NONSYN	1624	1626	CCC	1718	1720	CAC	11;11;11	C;A;C	6;6;6	.	.
penA.56.001	penA.56.001	1	1	531	192	penA	1719	1648	99.7	penA.l15.c4.ctg.1	1742	20.6	0	.	p	.	0	G548V	NONSYN	1642	1644	GGA	1736	1738	GTA	9;8;8	G;T;A	4;4;5	.	.
penA.56.001	penA.56.001	1	1	531	192	penA	1719	1648	99.7	penA.l15.c4.ctg.1	1742	20.6	1	SNP	p	A311V	0	.	.	931	933	GCA	1025	1027	GCA	21;22;22	G;C;A	12;10;12	penA.56.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.56.001	penA.56.001	1	1	531	192	penA	1719	1648	99.7	penA.l15.c4.ctg.1	1742	20.6	1	SNP	p	I312M	0	.	.	934	936	ATC	1028	1030	ATC	22;22;22	A;T,G;C	13;11,1;15	penA.56.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.56.001	penA.56.001	1	1	531	192	penA	1719	1648	99.7	penA.l15.c4.ctg.1	1742	20.6	1	SNP	p	V316P	0	.	.	946	948	GTG	1040	1042	GTG	21;21;21	G;T;G	15;11;12	penA.56.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.56.001	penA.56.001	1	1	531	192	penA	1719	1648	99.7	penA.l15.c4.ctg.1	1742	20.6	1	SNP	p	V316T	0	.	.	946	948	GTG	1040	1042	GTG	21;21;21	G;T;G	15;11;12	penA.56.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.56.001	penA.56.001	1	1	531	192	penA	1719	1648	99.7	penA.l15.c4.ctg.1	1742	20.6	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1544	1546	ACC	6;6;6	A;C;C	4;4;4	penA.56.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.56.001	penA.56.001	1	1	531	192	penA	1719	1648	99.7	penA.l15.c4.ctg.1	1742	20.6	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1721	1723	GGC	11;11;11	G;G;C	6;6;6	penA.56.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.56.001	penA.56.001	1	1	531	192	penA	1719	1648	99.7	penA.l15.c4.ctg.1	1742	20.6	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1730	1732	GGC	11;11;9	G;G;C	6;6;5	penA.56.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	370	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3230	20.6	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	98	porA	1146	1069	99.72	porA.l15.c17.ctg.1	1118	14.9	0	.	p	.	0	M83fs	FSHIFT	247	247	A	169	169	C	4	C	2	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	98	porB1b	1035	1035	95.82	porB1b.l15.c4.ctg.1	1525	13.4	0	.	p	.	0	E48G	NONSYN	142	144	GAA	431	433	GGA	11;11;11	G;G;A	8;7;8	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	98	porB1b	1035	1035	95.82	porB1b.l15.c4.ctg.1	1525	13.4	0	.	p	.	0	F135L	NONSYN	403	405	TTT	692	694	CTT	6;6;6	C;T;T	4;4;4	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	98	porB1b	1035	1035	95.82	porB1b.l15.c4.ctg.1	1525	13.4	0	.	p	.	0	R143G	NONSYN	427	429	AGA	716	718	GGA	4;6;6	G;G;A	3;4;4	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	98	porB1b	1035	1035	95.82	porB1b.l15.c4.ctg.1	1525	13.4	0	.	p	.	0	D171G	NONSYN	511	513	GAT	800	802	GGT	8;8;8	G;G;T	4;4;4	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	98	porB1b	1035	1035	95.82	porB1b.l15.c4.ctg.1	1525	13.4	0	.	p	.	0	G189S	NONSYN	565	567	GGC	854	856	AGC	9;9;9	A;G;C	5;5;5	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	98	porB1b	1035	1035	95.82	porB1b.l15.c4.ctg.1	1525	13.4	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	920	920	T	12	T	7	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	98	porB1b	1035	1035	95.82	porB1b.l15.c4.ctg.1	1525	13.4	1	SNP	p	G120K	0	.	.	358	360	GGT	647	649	GGT	7;8;8	G;G;T	4;5;5	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	98	porB1b	1035	1035	95.82	porB1b.l15.c4.ctg.1	1525	13.4	1	SNP	p	A121N	0	.	.	361	363	GCC	650	652	GCC	8;7;7	G;C;C	5;5;5	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	98	porB1b	1035	1035	95.82	porB1b.l15.c4.ctg.1	1525	13.4	1	SNP	p	A121D	0	.	.	361	363	GCC	650	652	GCC	8;7;7	G;C;C	5;5;5	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	530	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	4848	20.8	1	SNP	p	H553N	1	.	.	1657	1659	AAT	1916	1918	AAT	20;20;20	A;A;T	12;13;12	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	62	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	626	16.8	1	SNP	p	V57M	1	.	.	169	171	ATG	299	301	ATG	23;21;21	A;T;G	14;13;13	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
